We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Proposed Combination Products Rule Underestimates the Cost to Industry
Proposed Combination Products Rule Underestimates the Cost to Industry
January 11, 2010
The U.S. Food and Drug Administration’s (FDA) proposed rule on good manufacturing practices (GMPs) for combination products grossly underestimates
the burden of applying certain cGMP requirements to device-drug combinations, a device company says.
To View This Article:
Login
Subscribe To International Medical Device Regulatory Monitor